Prospective Multicenter International Surveillance of Azole Resistance in Aspergillus fumigatus

J. W. M. van der Linden; M. C. Arendrup; Aafje Warris; K. Lagrou; H. Pelloux; P. M. Hauser; E. Chryssanthou; E. Mellado; S. E. Kidd; A. M. Tortorano; E. Dannaoui; P. Gaustad; J. W. Baddley; A. Uekoetter; C. Lass-Floerl; N. Klimko; C. B. Moore; D. W. Denning; A. C. Pasqualotto; C. Kibbler; S. Arikan-Akdagli; D. Andes; J. Meletiadis; L. Naumiuk; M. Nucci; W. J. G. Melchers; P. E. Verweij

doi:10.3201/eid2106.140717

Prospective Multicenter International Surveillance of Azole Resistance in Aspergillus fumigatus

J. W. M. van der Linden^*, M. C. Arendrup, Aafje Warris, K. Lagrou, H. Pelloux, P. M. Hauser, E. Chryssanthou, E. Mellado, S. E. Kidd, A. M. Tortorano, E. Dannaoui, P. Gaustad, J. W. Baddley, A. Uekoetter, C. Lass-Floerl, N. Klimko, C. B. Moore, D. W. Denning, A. C. Pasqualotto, C. KibblerS. Arikan-Akdagli, D. Andes, J. Meletiadis, L. Naumiuk, M. Nucci, W. J. G. Melchers, P. E. Verweij

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

280 Citations (Scopus)

Abstract

To investigate azole resistance in clinical Aspergillus isolates, we conducted prospective multicenter international surveillance. A total of 3,788 Aspergillus isolates were screened in 22 centers from 19 countries. Azole-resistant A. fumigatus was more frequently found (3.2% prevalence) than previously acknowledged, causing resistant invasive and noninvasive aspergillosis and severely compromising clinical use of azoles.

Original language	English
Pages (from-to)	1041-1044
Number of pages	4
Journal	Emerging Infectious Diseases
Volume	21
Issue number	6
DOIs	https://doi.org/10.3201/eid2106.140717
Publication status	Published - Jun 2015

Bibliographical note

Acknowledgments

We thank Jan Zoll, Ton Rijs, Hein van der Lee, Diane Lamers-Jansen, and Birgit Brandt for excellent technical assistance. We also thank Monica Slavin, Orla Morrissey, and Alison Campbell for local site support.

This work was supported in part by an unrestricted research grant through the Investigator Initiated Studies Program (IISP) of Merck, Sharp & Dohme (MSD).

We declare that we have no conflicts of interest related to this study. J.L. received travel grants from Gilead and MSD and honorarium as a speaker from Pfizer. M.A. has received research grants, travel grants, and honorarium as a speaker or advisor from Astellas, Gilead, MSD, and Pfizer. A.W. received educational grants from Pfizer, Gilead, and MSD. K.L. received research grants from Gilead; Pfizer; and MSD and served on the speakers’ bureau of Pfizer and MSD. S.K. received research funds, travel grants, and honoraria as a speaker or advisor from Gilead, MSD, and Pfizer. E.D. received research grants, travel grants, and honorarium as a speaker or advisor from Astellas, Gilead, MSD, Bio-Rad, Ferrer International, Schering, and Innothera. P.G. received travel grants and honoraria as speaker from Astellas, Gilead, MSD, and Pfizer. J.B. served as a consultant for MSD, Pfizer, Astellas, and Mayne Pharma. C.M. received travel grants from Astellas, honorarium as a speaker from Pfizer, and grant support from Pfizer. C.K. received honoraria from Gilead, MSD, Pfizer, and Astellas. A.U. received a travel grant from Astellas and honoraria as a speaker from MSD and Pfizer. L.N. received travel grants from MSD and Pfizer. P.V. received research grants, has attended conferences, given lectures and participated in advisory boards or trials sponsored by various pharmaceutical companies.

Keywords

Azole resistance
Aspergillus fumigatus
Aspergillus diseases

Access to Document

10.3201/eid2106.140717Licence: Unspecified

Cite this

van der Linden, J. W. M., Arendrup, M. C., Warris, A., Lagrou, K., Pelloux, H., Hauser, P. M., Chryssanthou, E., Mellado, E., Kidd, S. E., Tortorano, A. M., Dannaoui, E., Gaustad, P., Baddley, J. W., Uekoetter, A., Lass-Floerl, C., Klimko, N., Moore, C. B., Denning, D. W., Pasqualotto, A. C., ... Verweij, P. E. (2015). Prospective Multicenter International Surveillance of Azole Resistance in Aspergillus fumigatus. Emerging Infectious Diseases, 21(6), 1041-1044. https://doi.org/10.3201/eid2106.140717

van der Linden, JWM, Arendrup, MC, Warris, A, Lagrou, K, Pelloux, H, Hauser, PM, Chryssanthou, E, Mellado, E, Kidd, SE, Tortorano, AM, Dannaoui, E, Gaustad, P, Baddley, JW, Uekoetter, A, Lass-Floerl, C, Klimko, N, Moore, CB, Denning, DW, Pasqualotto, AC, Kibbler, C, Arikan-Akdagli, S, Andes, D, Meletiadis, J, Naumiuk, L, Nucci, M, Melchers, WJG & Verweij, PE 2015, 'Prospective Multicenter International Surveillance of Azole Resistance in Aspergillus fumigatus', Emerging Infectious Diseases, vol. 21, no. 6, pp. 1041-1044. https://doi.org/10.3201/eid2106.140717

@article{ac11a154a4a047ba8d2d7d791a58087a,

title = "Prospective Multicenter International Surveillance of Azole Resistance in Aspergillus fumigatus",

abstract = "To investigate azole resistance in clinical Aspergillus isolates, we conducted prospective multicenter international surveillance. A total of 3,788 Aspergillus isolates were screened in 22 centers from 19 countries. Azole-resistant A. fumigatus was more frequently found (3.2% prevalence) than previously acknowledged, causing resistant invasive and noninvasive aspergillosis and severely compromising clinical use of azoles.",

keywords = "Azole resistance, Aspergillus fumigatus, Aspergillus diseases",

author = "{van der Linden}, {J. W. M.} and Arendrup, {M. C.} and Aafje Warris and K. Lagrou and H. Pelloux and Hauser, {P. M.} and E. Chryssanthou and E. Mellado and Kidd, {S. E.} and Tortorano, {A. M.} and E. Dannaoui and P. Gaustad and Baddley, {J. W.} and A. Uekoetter and C. Lass-Floerl and N. Klimko and Moore, {C. B.} and Denning, {D. W.} and Pasqualotto, {A. C.} and C. Kibbler and S. Arikan-Akdagli and D. Andes and J. Meletiadis and L. Naumiuk and M. Nucci and Melchers, {W. J. G.} and Verweij, {P. E.}",

note = "Acknowledgments We thank Jan Zoll, Ton Rijs, Hein van der Lee, Diane Lamers-Jansen, and Birgit Brandt for excellent technical assistance. We also thank Monica Slavin, Orla Morrissey, and Alison Campbell for local site support. This work was supported in part by an unrestricted research grant through the Investigator Initiated Studies Program (IISP) of Merck, Sharp & Dohme (MSD). We declare that we have no conflicts of interest related to this study. J.L. received travel grants from Gilead and MSD and honorarium as a speaker from Pfizer. M.A. has received research grants, travel grants, and honorarium as a speaker or advisor from Astellas, Gilead, MSD, and Pfizer. A.W. received educational grants from Pfizer, Gilead, and MSD. K.L. received research grants from Gilead; Pfizer; and MSD and served on the speakers{\textquoteright} bureau of Pfizer and MSD. S.K. received research funds, travel grants, and honoraria as a speaker or advisor from Gilead, MSD, and Pfizer. E.D. received research grants, travel grants, and honorarium as a speaker or advisor from Astellas, Gilead, MSD, Bio-Rad, Ferrer International, Schering, and Innothera. P.G. received travel grants and honoraria as speaker from Astellas, Gilead, MSD, and Pfizer. J.B. served as a consultant for MSD, Pfizer, Astellas, and Mayne Pharma. C.M. received travel grants from Astellas, honorarium as a speaker from Pfizer, and grant support from Pfizer. C.K. received honoraria from Gilead, MSD, Pfizer, and Astellas. A.U. received a travel grant from Astellas and honoraria as a speaker from MSD and Pfizer. L.N. received travel grants from MSD and Pfizer. P.V. received research grants, has attended conferences, given lectures and participated in advisory boards or trials sponsored by various pharmaceutical companies.",

year = "2015",

month = jun,

doi = "10.3201/eid2106.140717",

language = "English",

volume = "21",

pages = "1041--1044",

journal = "Emerging Infectious Diseases",

issn = "1080-6040",

publisher = "CENTERS DISEASE CONTROL",

number = "6",

}

TY - JOUR

T1 - Prospective Multicenter International Surveillance of Azole Resistance in Aspergillus fumigatus

AU - van der Linden, J. W. M.

AU - Arendrup, M. C.

AU - Warris, Aafje

AU - Lagrou, K.

AU - Pelloux, H.

AU - Hauser, P. M.

AU - Chryssanthou, E.

AU - Mellado, E.

AU - Kidd, S. E.

AU - Tortorano, A. M.

AU - Dannaoui, E.

AU - Gaustad, P.

AU - Baddley, J. W.

AU - Uekoetter, A.

AU - Lass-Floerl, C.

AU - Klimko, N.

AU - Moore, C. B.

AU - Denning, D. W.

AU - Pasqualotto, A. C.

AU - Kibbler, C.

AU - Arikan-Akdagli, S.

AU - Andes, D.

AU - Meletiadis, J.

AU - Naumiuk, L.

AU - Nucci, M.

AU - Melchers, W. J. G.

AU - Verweij, P. E.

N1 - Acknowledgments We thank Jan Zoll, Ton Rijs, Hein van der Lee, Diane Lamers-Jansen, and Birgit Brandt for excellent technical assistance. We also thank Monica Slavin, Orla Morrissey, and Alison Campbell for local site support. This work was supported in part by an unrestricted research grant through the Investigator Initiated Studies Program (IISP) of Merck, Sharp & Dohme (MSD). We declare that we have no conflicts of interest related to this study. J.L. received travel grants from Gilead and MSD and honorarium as a speaker from Pfizer. M.A. has received research grants, travel grants, and honorarium as a speaker or advisor from Astellas, Gilead, MSD, and Pfizer. A.W. received educational grants from Pfizer, Gilead, and MSD. K.L. received research grants from Gilead; Pfizer; and MSD and served on the speakers’ bureau of Pfizer and MSD. S.K. received research funds, travel grants, and honoraria as a speaker or advisor from Gilead, MSD, and Pfizer. E.D. received research grants, travel grants, and honorarium as a speaker or advisor from Astellas, Gilead, MSD, Bio-Rad, Ferrer International, Schering, and Innothera. P.G. received travel grants and honoraria as speaker from Astellas, Gilead, MSD, and Pfizer. J.B. served as a consultant for MSD, Pfizer, Astellas, and Mayne Pharma. C.M. received travel grants from Astellas, honorarium as a speaker from Pfizer, and grant support from Pfizer. C.K. received honoraria from Gilead, MSD, Pfizer, and Astellas. A.U. received a travel grant from Astellas and honoraria as a speaker from MSD and Pfizer. L.N. received travel grants from MSD and Pfizer. P.V. received research grants, has attended conferences, given lectures and participated in advisory boards or trials sponsored by various pharmaceutical companies.

PY - 2015/6

Y1 - 2015/6

N2 - To investigate azole resistance in clinical Aspergillus isolates, we conducted prospective multicenter international surveillance. A total of 3,788 Aspergillus isolates were screened in 22 centers from 19 countries. Azole-resistant A. fumigatus was more frequently found (3.2% prevalence) than previously acknowledged, causing resistant invasive and noninvasive aspergillosis and severely compromising clinical use of azoles.

AB - To investigate azole resistance in clinical Aspergillus isolates, we conducted prospective multicenter international surveillance. A total of 3,788 Aspergillus isolates were screened in 22 centers from 19 countries. Azole-resistant A. fumigatus was more frequently found (3.2% prevalence) than previously acknowledged, causing resistant invasive and noninvasive aspergillosis and severely compromising clinical use of azoles.

KW - Azole resistance

KW - Aspergillus fumigatus

KW - Aspergillus diseases

U2 - 10.3201/eid2106.140717

DO - 10.3201/eid2106.140717

M3 - Article

SN - 1080-6040

VL - 21

SP - 1041

EP - 1044

JO - Emerging Infectious Diseases

JF - Emerging Infectious Diseases

IS - 6

ER -

Prospective Multicenter International Surveillance of Azole Resistance in Aspergillus fumigatus

Abstract

Bibliographical note

Keywords

Access to Document

Fingerprint

Cite this